

Supplementary Table 1

	First line treatment in the CT only group	CRT + adjuvant CT	Neo-CT + CRT	CRT only
<i>Chemotherapy regimens used in first line, n=30</i>				
<i>Carboplatin + paclitaxel</i>	4	0	3	0
<i>Carboplatin + paclitaxel + bevacizumab</i>	4	0	3	0
<i>Cisplatin + gemcitabine</i>	0	3	0	0
<i>Carboplatin + paclitaxel + bevacizumab + pembrolizumab</i>	1	0	0	0
<i>Cisplatin + topotecan</i>	1	2	0	0
<i>Cisplatin</i>	0	0	0	9
<i>Immunotherapy used in second treatment line, n=11</i>				
<i>Pembrolizumab (second line)</i>	1	1	1	2
<i>Clinical trial - MK 7684 Pembrolizumab + vibostolimab</i>	4	0	0	0
<i>Clinical trial - NeoTx (durvalumab + naptumumab)</i>	1	0	0	0
<i>Clinical trial - MK 58909 (pembrolizumab)</i>	0	0	1	0
<i>Immunotherapy used advanced treatment line, n=3</i>				
<i>Pembrolizumab (second line)</i>	0	0	0	0
<i>Clinical trial - MK 7684 (pembrolizumab + vibostolimab)</i>	0	1	0	0
<i>Nivolumab</i>	1	0	0	0

Abbreviations: Chemotherapy (CT), Chemoradiation (CRT), Number (n), Neoadjuvant chemotherapy (Neo-CT)